Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Res Cardiol. 2008 Apr;97(4):222-6. Epub 2007 Nov 28.

Mechanism of action of the new anti-ischemia drug ranolazine.

Author information

  • 1Dept. of Cardiology and Pneumology, Heart Center Göttingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany. hasenfus@med.uni-goettingen.de

Abstract

Myocardial ischemia is associated with reduced ATP fluxes and decreased energy supply resulting in disturbances of intracellular ion homeostasis in cardiac myocytes. In the recent years, increased persistent (late) sodium current was suggested to contribute to disturbed ion homeostasis by elevating intracellular sodium concentration with subsequent elevation of intracellular calcium. The new anti-ischemia drug ranolazine, a specific inhibitor of late sodium current, reduces sodium overload and hence ameliorates disturbed ion homeostasis. This is associated with symptomatic improvement of angina in patients. Moreover, ranolazine was shown to exhibit anti-arrhythmic effects. In the present article, we review the relevant pathophysiological concepts for the role of late sodium inhibition and summarize the most recent data from basic as well as clinical studies.

PMID:
18046526
[PubMed - indexed for MEDLINE]
PMCID:
PMC3085780
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk